Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by WORKINMONTANAon Mar 21, 2019 11:00pm

101 Views

Post# 29520995

RE:3 theories

Can someone post net house positions from the last two days? Let’s see if 3 is the answer. I saw a lot of anonymous, RBC and TD in accumulation.

Thejew wrote: 1. A bunch of stoned penny investors picked the wrong ticker and mistakenly blew up Kalytera instead of Kali.

2. Because it's an open label study (correct me if I am wrong) a larger company likes where the trial is going and is doing some type of partnership and loose lips have people buying up the stock.

3. People are anticipating first cohort results, the stock has bottomed out and dilution has dried up all around the same time and people are buying it up and simultaneously some dudes taking bong hits bought the wrong ticker and helped the volume.

I'm thinking 3.